Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing’s disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study

Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing’s disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study

IntroductionPasireotide, a somatostatin receptor ligand, is approved for treating acromegaly and Cushing’s disease (CD). Hyperglycemia during treatment can occur because of the drug’s mechanism of action, although treatment discontinuation is rarely required. The prospective, randomized, Phase IV SO...

Full description

Bibliographic Details
Main Authors: Ulla Feldt-Rasmussen, Marek Bolanowski, Shao-Ling Zhang, Yerong Yu, Przemysław Witek, Pramila Kalra, Noppadol Kietsiriroje, Andrea Piacentini, Alberto M. Pedroncelli, Susan L. Samson
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Endocrinology
Subjects:
hyperglycemia
glucose intolerance
diabetes mellitus
pasireotide
acromegaly
Cushing’s disease
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2024.1250822/full

Similar Items

Similar Items